William Blair analyst Brandon Vazquez has maintained their bullish stance on CBLL stock, giving a Buy rating on August 17.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brandon Vazquez has given his Buy rating due to a combination of factors, primarily focusing on Ceribell, Inc.’s recent commercial investments and strategic initiatives. The company has made significant strides by hiring new territory managers and implementing account protocols aimed at standardizing EEG testing for specific patient groups. These efforts, although in their early stages, are showing promising trends and are expected to contribute positively in the latter half of the year.
Moreover, the management’s conservative guidance for the second half reflects a cautious optimism, but the ongoing momentum of these initiatives is anticipated to yield favorable outcomes. Additionally, the potential for pipeline products, particularly in the pediatric sector, is seen as a catalyst for future growth, with expectations of significant impact by 2026 and beyond. With the stock trading at a reasonable multiple of the 2026 sales estimate, Vazquez maintains a positive outlook on Ceribell’s growth trajectory, reinforcing the Buy rating.
In another report released on August 17, TD Cowen also reiterated a Buy rating on the stock with a $36.00 price target.